Reverting immune suppressionto elicit brain metastasis control
About us*
The RISEbrain consortium brings together the highly complementary expertise of 6 teams with inter-sectorial (basic and clinical) and interdisciplinary focus (life sciences, computational sciences, engineering) to tackle the growing societal challenge posed by brain metastases.

Partners*
RISEbrain brings together 6 partners with diverse backgrounds and expertise. Learn more about our team on our website.
Positions available*
We currently have job openings available! If you are interested check out our website for more information on how to apply.
Consortium achievements*
At RISEBrain, each laboratory has achieved significant scientific achievements in their respective fields of study. Visit our website to learn more about our achievements and ongoing research.
- Marc Schmitz
Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer
J Immunother Cancer
- Manuel Valiente
Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism.
Monteiro, Miarka et al.
Nature Medicine
- Manuel Valiente
STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis
Priego et al.
Nature Medicine (2018)
- Marc Schmitz
Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T-cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia
Blood
- Luca Bertero
Prognostic Characterization of Higher-Grade Meningiomas: A Histopathological Score to Predict Progression and Outcome.
Journal of Neuropathology & Experimental Neurology 2019 Mar 1;78(3):248-256
- Luca Bertero
Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA.
Acta Neuropathologica 2019 May;137(5):837-846
News & Outreach*
Our RISEbrain partners have been published and featured in top media outlets and conferences. Learn more on our website.
2023
- Luca Bertero
Clinical studies
SILMET
A controlled, randomized, double-blind clinical trial to evaluate the efficacy of SILbinin versus placebo to prevent recurrence after surgical resection of a single brain METastasis from non-small cell lung carcinoma or breast carcinoma
2023
- Marc Schmitz
Grants
SaxoCell: Development of theranostic target molecules for diagnosis and therapy
Funding Organisation: Federal Ministry of Education and Research
2023
- Luca Bertero
Grant for internationalization
Molecular dissection of ovarian cancer brain metastasis microenvironment through spatial transcriptomics
Project partners: Pathology unit, Department of Medical Sciences, University of Turin, Italy and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College, London, UK
Amount: 55.481,46€
10/2013
- Hind Medyouf
Invited Speaker
European Macrophage and Dendritic cell society (EMDS) meeting
VIB Ghent, Belgium
06/2023
- Hind Medyouf
Invited speaker
European Hematology Association Annual meeting
Frankfurt, Germany